A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
- Interventions
- Registration Number
- NCT03038100
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1301
- Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC), peritoneal primary carcinoma, or fallopian tube cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Life expectancy greater than (>) 12 weeks
- For participants who receive therapeutic anticoagulation: stable anticoagulant regimen
- Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in paraffin blocks (preferred) or at least 20 unstained slides (for detailed tissue requirements at screening)
- Received a current diagnosis of borderline epithelial ovarian tumor (formerly tumors of low malignant potential)
- Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer that was treated only with surgery (example [e.g.], participants with Stage IA or Stage IB epithelial ovarian or fallopian tube cancers)
- Have non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord stromal tumors)
- Received prior radiotherapy to any portion of the abdominal cavity or pelvis
- Received prior chemotherapy for any abdominal or pelvic tumor that include neoadjuvant chemotherapy (NACT) for ovarian, primary peritoneal or fallopian tube cancer
- Received any biological and/or targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management and/or treatment of epithelial ovarian or peritoneal primary cancer
- Have synchronous primary endometrial cancer
- Have a prior history of primary endometrial cancer, except: Stage IA cancer; superficial myometrial invasion, without lymphovascular invasion; grade less than (<) 3 or poorly differentiated subtypes, and this includes papillary serous, clear cell or other International Federation of Gynecological Oncologists (FIGO) Grade 3 lesions
- With the exception of non-melanoma skin cancer and other specific malignancies as noted above, other invasive malignancies with any evidence of other cancers present within the last 5 years or previous cancer treatment that contraindicates this protocol therapy
- Have a known hypersensitivity or allergy to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab formulations
- Undergo major surgical procedure within 28 days prior to first bevacizumab dose, or anticipation of the need for a major surgical procedure during the course of the study except participants who receive NACT and will need interval surgery. This may include but is not limited to laparotomy.
- Have prior allogeneic bone marrow transplantation or solid organ transplant
- Have any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results
- Have any approved or investigational anti-cancer therapy, including chemotherapy or hormonal therapy, with exceptions: Hormone-replacement therapy or oral contraceptives
- Are administered treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intent
- Have core biopsy or other minor surgical procedures within 7 days prior to the first dose of bevacizumab
- Have known sensitivity to any component of bevacizumab
- Have known sensitivity to any component of paclitaxel
- Current treatment with anti-viral therapy for hepatitis B virus (HBV)
- History of leptomeningeal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo With Paclitaxel, Carboplatin and Bevacizumab Atezolizumab Placebo Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles. Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Paclitaxel Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles. Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Carboplatin Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles. Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Atezolizumab Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles. Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Bevacizumab Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles. Placebo With Paclitaxel, Carboplatin and Bevacizumab Paclitaxel Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles. Placebo With Paclitaxel, Carboplatin and Bevacizumab Carboplatin Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles. Placebo With Paclitaxel, Carboplatin and Bevacizumab Bevacizumab Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population From randomization until disease progression or death from any cause (up to approximately 55 months) Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation From randomization until disease progression or death from any cause (up to approximately 55 months) Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Overall Survival - PD-L1-Positive Subpopulation From randomization up to death from any cause (up to approximately 59 months) Overall Survival (OS) is defined as the time from randomization to death from any cause.
Overall Survival - ITT Population From randomization up to death from any cause (up to approximately 59 months) Overall Survival (OS) is defined as the time from randomization to death from any cause.
- Secondary Outcome Measures
Name Time Method Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months) DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. Clinically-meaningful improvement in patient-reported function and HRQoL during the treatment period, defined as a \>=10-point increase from the baseline score on each of the functional (social, emotional, physical, role) and GHS/QoLscales of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30).
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population From randomization until disease progression or death from any cause (up to approximately 55 months) OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population From randomization until disease progression or death from any cause (up to approximately 55 months) OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. Percentage of participants with clinical improvement, defined as \>= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab Baseline to approximately 55 months Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months) DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. Clinically-meaningful improvement defined as a \>=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. Percentage of participants who remain stable defined as changes within 10 points from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months). Cycle length=21 days. Percentage of participants with deterioration in patient-reported function and HRQoL, defined as \>= 10 points decrease from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Percentage of Participants With at Least One Adverse Event From randomization up to approximately 59 months Percentage of participants with at least one adverse event.
Maximum Serum Concentration (Cmax) of Atezolizumab Cycle 1 Day 1 post dose and Cycle 3 Day 1 post dose Minimum Serum Concentration (Cmin) of Atezolizumab Cycle 2 Day 1 predose, Cycle 3 Day 1 Predose, Cycle 4 Day 1 predose, Cycle 8 Day 1 predose, Cycle 16 Day 1 predose
Trial Locations
- Locations (267)
Columbus NCORP
🇺🇸Columbus, Ohio, United States
Ohio State University, Arthur James Cancer Hospital
🇺🇸Columbus, Ohio, United States
Greater Baltimore Medical Center
🇺🇸Baltimore, Maryland, United States
Sinai Hospital of Baltimore
🇺🇸Baltimore, Maryland, United States
Western Pennsylvania Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Univ of Chicago
🇺🇸Chicago, Illinois, United States
University of Iowa Hospital & Clinic; Division of Hematology/Oncology
🇺🇸Iowa City, Iowa, United States
Kaiser Permanente - Walnut Creek
🇺🇸Walnut Creek, California, United States
Eastern Connecticut Hematology and Oncology Associates; (ECHO)
🇺🇸Norwich, Connecticut, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Parkview Research Center
🇺🇸Fort Wayne, Indiana, United States
Northeast Georgia Medical Center; Oncology Research Dept-5C
🇺🇸Gainesville, Georgia, United States
St. Elizabeth Edgewood; Cancer Care Center? for Account St. Elizabeth Edgewood
🇺🇸Edgewood, Kentucky, United States
Sarasota Memorial Health Care System; Cancer Research Program
🇺🇸Sarasota, Florida, United States
Olive View/Ucla Medical Center
🇺🇸Sylmar, California, United States
Northside Hospital
🇺🇸Atlanta, Georgia, United States
Kaiser Permanente - Santa Clara
🇺🇸Santa Clara, California, United States
West China Second University Hospital
🇨🇳Chengdu City, China
Sanford Roger Maris Cancer Center
🇺🇸Fargo, North Dakota, United States
Center of Hope
🇺🇸Reno, Nevada, United States
MSK @Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
New York Univ Medical Center; Obstetrics & Gynecolog
🇺🇸New York, New York, United States
Women & Infants Hospital
🇺🇸Providence, Rhode Island, United States
Sanford Health Bemidji
🇺🇸Bemidji, Minnesota, United States
Memorial Sloan Kettering Cancer Center; MSK Monmouth
🇺🇸Middletown, New Jersey, United States
St. Dominic-Jackson Memorial Hospital
🇺🇸Jackson, Mississippi, United States
Billings Clinic; Cancer Center
🇺🇸Billings, Montana, United States
Holy Name Hospital
🇺🇸Teaneck, New Jersey, United States
Minnesota Oncology Hematology Woodbury
🇺🇸Woodbury, Minnesota, United States
Womens Cancer Care Association
🇺🇸Albany, New York, United States
Northwest Cancer Specialists, P.C.
🇺🇸Tigard, Oregon, United States
New York Presbyterian Queens
🇺🇸Flushing, New York, United States
Munson Medical Center
🇺🇸Traverse City, Michigan, United States
Community Cancer Care
🇺🇸Missoula, Montana, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Temple University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Fairview Hospital; Cleveland Clinic Cancer Center
🇺🇸Cleveland, Ohio, United States
Novant Health Presbyterain Medical Center
🇺🇸Charlotte, North Carolina, United States
Cooper Health System; MD Anderson Cancer Center
🇺🇸Camden, New Jersey, United States
Jersey Shore Med Ctr; OB/GYN
🇺🇸Neptune, New Jersey, United States
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Hannover, Germany
Cabrini Hospital; Cabrini Foundation
🇦🇺Malvern, Victoria, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
🇦🇹Innsbruck, Austria
Universitätsklinikum Freiburg; Frauenklinik
🇩🇪Freiburg, Germany
Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum
🇩🇪Greifswald, Germany
Azienda Ospedaliera Universitaria Federico II
🇮🇹Napoli, Campania, Italy
Kaplan Medical Center; Oncology Inst.
🇮🇱Rehovot, Israel
Shaare Zedek Medical Center; Oncology Dept
🇮🇱Jerusalem, Israel
EUROMEDICA General Clinic of Thessaloniki; Medical Oncology Dept - Oncomedicare
🇬🇷Thessaloniki, Greece
Arcispedale Santa Maria Nuova; Oncologia
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico
🇮🇹Napoli, Campania, Italy
Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
🇩🇪Essen, Germany
Klinikum Südstadt
🇩🇪Rostock, Germany
Klinikum Konstanz, Frauenklinik
🇩🇪Konstanz, Germany
Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde
🇩🇪Muenchen, Germany
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
🇩🇪Mainz, Germany
Hillel Yaffe MC; Gynaecology
🇮🇱Hadera, Israel
Universitätsklinikum Ulm Am Michelsberg; Frauenklinik
🇩🇪Ulm, Germany
Universitätsklinikum Heidelberg; Nationales Centrum für Tumorerkrankungen (NCT)
🇩🇪Heidelberg, Germany
NHO Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Ospedale Degli Infermi - Faenza; Oncologia Medica
🇮🇹Faenza, Emilia-Romagna, Italy
National Hospital Organization Shikoku Cancer Center
🇯🇵Ehime, Japan
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Lübeck, Germany
Meir Medical Center; Obstetrics and Gynecology
🇮🇱Kfar Saba, Israel
Tohoku University Hospital
🇯🇵Miyagi, Japan
Kliniken Essen Mitte Evang. Huyssens Stiftung/Knappschaft GmbH
🇩🇪Essen, Germany
Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde
🇩🇪München, Germany
Universitätsklinikum Hamburg-Eppendorf (UKE); Klinik und Poliklinik für Gynäkologie
🇩🇪Hamburg, Germany
Clinique Sainte Catherine; Hopital De Semaine
🇫🇷Avignon, France
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Uni Hospital of Ioannina; Oncology Dept.
🇬🇷Ioannina, Greece
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie;Klinika Ginekologii Onkologicznej
🇵🇱Warszawa, Poland
Ehime University Hospital
🇯🇵Ehime, Japan
Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
🇮🇹Milano, Lombardia, Italy
Kagoshima University Hospital
🇯🇵Kagoshima, Japan
Chaim Sheba Medical Center; Obstetrics and Gynecology
🇮🇱Ramat Gan, Israel
Hyogo Cancer Center
🇯🇵Hyogo, Japan
Policlinico S.Orsola-Malpighi; Istituto Oncologia R. Addarii
🇮🇹Bologna, Emilia-Romagna, Italy
Alexandras Hospital; Dept. of Clin. Therapeutics, Athens Uni School of Medicine
🇬🇷Athens, Greece
Osaka International Cancer Institute
🇯🇵Osaka, Japan
The Jikei University Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
🇮🇹Meldola, Emilia-Romagna, Italy
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Nagoya University Hospital
🇯🇵Aichi, Japan
Policlinico A. Gemelli e C.I.C.; Area Salute della Donna
🇮🇹Roma, Lazio, Italy
St. Olavs Hospital
🇳🇴Trondheim, Norway
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Kyoto University Hospital
🇯🇵Kyoto, Japan
Kure Medical Center
🇯🇵Hiroshima, Japan
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Baskent Universitesi Ankara Hastanesi; T?bbi Onkoloji Bölümü
🇹🇷Ankara, Turkey
Koc University Medical Faculty; Department of Gynecology & Obstetrics
🇹🇷Istanbul, Turkey
Yokohama City University Hospital
🇯🇵Kanagawa, Japan
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
N.N.Burdenko Main Military Clinical Hospital; Oncology Dept
🇷🇺Moscow, Russian Federation
Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica
🇪🇸Barcelona, Spain
Oslo Universitetssykehus HF; Radiumhospitalet
🇳🇴Oslo, Norway
Uni Hospital Linkoeping; Dept. of Oncology
🇸🇪Linköping, Sweden
Keio University Hospital
🇯🇵Tokyo, Japan
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
🇪🇸Sabadell, Barcelona, Spain
Centro Integral Oncologico Clara Campal; Servicio de Oncología
🇪🇸Madrid, Spain
Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu; Oddzia? Ginekologii Onkologicznej
🇵🇱Pozna?, Poland
Icu Spsk - 2
🇵🇱Szczecin, Poland
Hospital Universitario Son Espases
🇪🇸Palma de Mallorca, Islas Baleares, Spain
Istanbul Uni Istanbul Medical Faculty
🇹🇷Istanbul, Turkey
Moscow City Oncology Hospital #62
🇷🇺Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation
Fundacion Hospital de Alcorcon; Servicio de Oncologia
🇪🇸Alcorcon, Madrid, Spain
Karolinska Hospital; Oncology - Radiumhemmet
🇸🇪Stockholm, Sweden
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
🇷🇺Kazan, Russian Federation
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
🇹🇷Adana, Turkey
Ankara University Medical Faculty; Medikal Onkoloji
🇹🇷Ankara, Turkey
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Istanbul University Cerrahpasa Medical Faculty; Obstetrics and Gynecology
🇹🇷Istanbul, Turkey
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
Weinberg CA Inst Franklin Sq
🇺🇸Baltimore, Maryland, United States
Frederick Health Hospital
🇺🇸Frederick, Maryland, United States
Sylvester Comprehensive Cent.
🇺🇸Miami, Florida, United States
Miami Cancer Institute of Baptist Health, Inc.
🇺🇸Miami, Florida, United States
St.Vincent Health System; Gynecologic Oncology
🇺🇸Indianapolis, Indiana, United States
University of Washington Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Southern California Kaiser Permanente
🇺🇸San Diego, California, United States
Women's Cancer Center
🇺🇸Las Vegas, Nevada, United States
Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept.
🇬🇷Kifisia, Greece
University Hospital of Patras Medical Oncology
🇬🇷Patras, Greece
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Duke Medical Center
🇺🇸Durham, North Carolina, United States
Texas Oncology San Antonio Medical Center
🇺🇸San Antonio, Texas, United States
Ospedale Silvestrini; Oncologia ed Ematologia
🇮🇹Perugia, Umbria, Italy
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Peking Union Medical College Hospital
🇨🇳Beijing City, China
Women's hospital school of medicine Zhejiang University
🇨🇳Hangzhou, China
Rigshospitalet; Onkologisk Klinik
🇩🇰København Ø, Denmark
California Pacific Medical Center Research Institute
🇺🇸San Francisco, California, United States
K. Permanente - San Fransisco
🇺🇸San Francisco, California, United States
University of California San Francisco Cancer Center
🇺🇸San Francisco, California, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
St. Joseph'S Hospital & Medical Center
🇺🇸Phoenix, Arizona, United States
University of Oklahoma; Stephenson Oklahoma Canc Ctr
🇺🇸Oklahoma City, Oklahoma, United States
A.O.Spedali Civili; Ostetricia e Ginecologia
🇮🇹Brescia, Lombardia, Italy
IRCCS S. Raffaele; Ginecologia Oncologica
🇮🇹Milano, Lombardia, Italy
Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica
🇮🇹Milano, Lombardia, Italy
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
🇮🇹Milano, Lombardia, Italy
A.O. San Gerardo; Ginecologia
🇮🇹Monza, Lombardia, Italy
A. O. Città della Salute e della Scienza; Unità di Oncologia Ginecologica
🇮🇹Torino, Piemonte, Italy
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
🇮🇹Padova, Veneto, Italy
Hopital Des Diaconesses; Oncologie
🇫🇷Paris, France
Mie University Hospital
🇯🇵Mie, Japan
The University of Tokyo Hospital
🇯🇵Tokyo, Japan
Hospital Universitario la Fe; Servicio de Oncologia
🇪🇸Valencia, Spain
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Klinik für Gynäkologie und gynäkologische Onkologie
🇩🇪Wiesbaden, Germany
Mount Sinai Downtown Chelsea Centre
🇺🇸New York, New York, United States
Arizona Oncology Associates, PC - HAL
🇺🇸Scottsdale, Arizona, United States
Arizona Oncology - HOPE Wilmot
🇺🇸Tucson, Arizona, United States
Moores Cancer Center at UC San Diego Health
🇺🇸La Jolla, California, United States
UCLA - School of Medicine
🇺🇸Los Angeles, California, United States
UC Irvine Medical Center
🇺🇸Orange, California, United States
Kaiser Permanente - Oakland
🇺🇸Oakland, California, United States
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
🇺🇸Orange, California, United States
Kaiser Permanente - Sacramento
🇺🇸Roseville, California, United States
Stanford University
🇺🇸Palo Alto, California, United States
Women's Cancer Associates
🇺🇸Saint Petersburg, Florida, United States
Sudarshan K. Sharma, MD, Ltd.
🇺🇸Hinsdale, Illinois, United States
Maine Medical Partners Women's Health; Gyn-Oncology
🇺🇸Scarborough, Maine, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Baystate Medical Center
🇺🇸Springfield, Massachusetts, United States
Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology
🇺🇸Saint Louis, Missouri, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
University of New Mexico Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Southwest Gynecologic Oncology Associates, Inc.
🇺🇸Albuquerque, New Mexico, United States
Memorial Sloan-Kettering CC
🇺🇸Rockville Centre, New York, United States
Northwell Health; Monter Cancer Center
🇺🇸Lake Success, New York, United States
Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
Sanford Health Bismarck
🇺🇸Bismarck, North Dakota, United States
University of Pennsylvania Health System; Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute
🇺🇸Springfield, Oregon, United States
Oklahoma Cancer Specialists and Research Institute
🇺🇸Tulsa, Oklahoma, United States
Magee-Woman's Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins
🇺🇸Willow Grove, Pennsylvania, United States
WellSpan Gynecologic Oncology
🇺🇸York, Pennsylvania, United States
Monument Health Rapid City Hospital, Inc.
🇺🇸Rapid City, South Dakota, United States
Bon Secours - St. Francis Hospital
🇺🇸Greenville, South Carolina, United States
Sanford Health System
🇺🇸Sioux Falls, South Dakota, United States
UT Southwestern Medical Center at Dallas; Department of Pathology
🇺🇸Dallas, Texas, United States
Texas Oncology
🇺🇸Bedford, Texas, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Texas Oncology- Northeast Texas
🇺🇸Tyler, Texas, United States
Dixie Medical Center
🇺🇸Saint George, Utah, United States
Texas Oncology, P.A. - Fort Worth
🇺🇸Fort Worth, Texas, United States
Texas Oncology, P.A.
🇺🇸The Woodlands, Texas, United States
Rocky Mountain Cancer Centers, LLP
🇺🇸Irving, Texas, United States
Houston Methodist Hospital
🇺🇸Houston, Texas, United States
Huntsman Cancer Institute; Oncology
🇺🇸Salt Lake City, Utah, United States
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Shenandoah Oncology Associates
🇺🇸Winchester, Virginia, United States
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
Aspirus Regional Cancer Center
🇺🇸Wausau, Wisconsin, United States
The Royal North Shore Hospital; Northern Sydney Cancer Centre
🇦🇺St Leonards, New South Wales, Australia
Peter MacCallum Cancer Center
🇦🇺North Melbourne, Victoria, Australia
Landeskrankenhaus Salzburg; Gynäkologie Und Onkologie
🇦🇹Salzburg, Austria
Krankenhaus Der Barmherzigen Brüder Graz; Gynäkologie
🇦🇹Graz, Austria
UZ Gent
🇧🇪Gent, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
Sint Augustinus Wilrijk
🇧🇪Wilrijk, Belgium
Instituto Nacional de Cancer - INCa; Oncologia
🇧🇷Rio de Janeiro, RJ, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
🇧🇷Sao Paulo, SP, Brazil
Beijing Cancer Hospital
🇨🇳Beijing, China
Sun Yet-sen University Cancer Center
🇨🇳Guangzhou City, China
Chongqing Cancer Hospital
🇨🇳Chongqing, China
Zhongda Hospital Affiliated to Southeast University
🇨🇳Nanjing, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Guangxi Cancer Hospital of Guangxi Medical University
🇨🇳Nanning, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
🇨🇳Nanjing City, China
Tianjin Central Hospital of Gynecology Obstetrics.
🇨🇳Tianjin City, China
Zhejiang Cancer Hospital
🇨🇳Zhejiang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Fakultni nemocnice Olomouc; Onkologicka klinika
🇨🇿Olomouc, Czechia
University Hospital Ostrava; Fakultní nemocnice
🇨🇿Ostrava-Poruba, Czechia
Onkologicka klinika UK 2.LF a FN v Motole
🇨🇿Praha 5, Czechia
Kuopio University Hospital
🇫🇮Kuopio, Finland
Gynekologicko-porodnicka klinika
🇨🇿Prague, Czechia
Tampereen yliopistollinen sairaala
🇫🇮Tampere, Finland
Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd
🇫🇷Le Mans, France
Centre Léon Bérard; Centre régional; le cancer Rhône-Alpes
🇫🇷Lyon, France
l'Hôpital privé du Confluent SAS
🇫🇷Nantes, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre Benite, France
Centre Rene Huguenin; CONSULT SPECIALISEES
🇫🇷St Cloud, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Campus Virchow-Klinikum Charité; Centrum 17; Klinik für Gynäkologie
🇩🇪Berlin, Germany
Universitätsklinikum Dresden; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Dresden, Germany
Ospedale Mauriziano Umberto 1; Ginecologia - Oncologia
🇮🇹Torino, Piemonte, Italy
Ospedale Antonio Perrino; Oncologia Medica
🇮🇹Brindisi, Puglia, Italy
Iwate Medical University Hospital
🇯🇵Iwate, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Hokkaido, Japan
Kurume University Hospital
🇯🇵Fukuoka, Japan
Niigata University Medical & Dental Hospital
🇯🇵Niigata, Japan
Centrum Onkologii Instytut im. M.Sklodowskiej-Curie; Klinika Ginekologii Onkologicznej
🇵🇱Krakow, Poland
St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary
🇷🇺Saint-Petersburg, Russian Federation
LAC + USC Medical Center
🇺🇸Los Angeles, California, United States
University of Kentucky; Gynecologic Oncology
🇺🇸Lexington, Kansas, United States
Univ Hospitals of Cleveland
🇺🇸Cleveland, Ohio, United States
Woman's Hospital
🇺🇸Baton Rouge, Louisiana, United States
John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
DN Greenwald Center
🇺🇸Mukwonago, Wisconsin, United States
University of Colorado Hospital - Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Nebraska Methodist Hospital
🇺🇸Omaha, Nebraska, United States
St. Joseph Mercy Hospital
🇺🇸Ann Arbor, Michigan, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists
🇺🇸Winston-Salem, North Carolina, United States
Wake Forest Baptist Medical Center
🇺🇸Winston-Salem, North Carolina, United States
Danbury Hospital
🇺🇸Danbury, Connecticut, United States
Metro-Minnesota Community Oncology Research Consortium
🇺🇸Saint Louis Park, Minnesota, United States
Kettering Medical Center
🇺🇸Kettering, Ohio, United States
Turku Uni Central Hospital; Gynaecology Dept
🇫🇮Turku, Finland
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
🇦🇹Wien, Austria
University of Virginia
🇺🇸Charlottesville, Virginia, United States
University of Cincinnati
🇺🇸Cincinnati, Ohio, United States
Dell Seton Medical Center at UT-Seton Infusion Center; Research Department
🇺🇸Austin, Texas, United States
Texas Oncology Cancer Center
🇺🇸Austin, Texas, United States
Henrico Doctors' Hospital - Forest
🇺🇸Richmond, Virginia, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States